Since the discovery of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, the virus’s dynamicity has resulted in the evolution of various variants, including the delta variant and the more novel mu variant. With a multitude of mutant strains posing as challenges to vaccine efficacy, it is critical that researchers embrace the development of pharmacotherapeutics specific to SARS-CoV-2 pathophysiology. Neutrophil extracellular traps and their constituents, including citrullinated histones, display a linear connection with thrombotic manifestations in COVID-19 patients. Peptidylarginine deiminases (PADs) are a group of enzymes involved in the modification of histone arginine residues by citrullination, allowing for the formation of NETs. PAD inhibitors, specifically PAD-4 inhibitors, offer extensive pharmacotherapeutic potential across a broad range of inflammatory diseases such as COVID-19, through mediating NETs formation. Although numerous PAD-4 inhibitors exist, current literature has not explored the depth of utilizing these inhibitors clinically to treat thrombotic complications in COVID-19 patients. This review article offers the clinical significance of PAD-4 inhibitors in reducing thrombotic complications across various inflammatory disorders like COVID-19 and suggests that these inhibitors may be valuable in treating the origin of SARS-CoV-2 immunothrombosis.
【저자키워드】 COVID-19, SARS-CoV2, PAD, NET, 【초록키워드】 Evolution, SARS-CoV-2, Efficacy, Vaccine, coronavirus, variant, inhibitors, variants, immunothrombosis, pathophysiology, inhibitor, Critical, NETs, COVID-19 patients, mutant strain, manifestation, connection, acute respiratory syndrome, inflammatory disorder, enzyme, thrombotic, treat, Modification, inflammatory disease, offer, researcher, thrombotic complication, citrullinated histones, involved, clinically, linear, reducing, arginine residue, extracellular trap, 【제목키워드】 SARS-CoV-2, Potential,